In the News
Aim to get back to around 20% revenue growth in FY18: Syngene
Money Control-28/04/2017. The tie-up with the Canadia Company is a good start for the biologics business...
Biologics and Biosimilars -Promising field for medicines for the future by Dr. Dhananjay Patankar (Head-Pharmaceutical and Biopharmaceutical Development)
Pharma Focus Asia-09/03/2017. As per Make in India campaign by the government, Indian biotech industry, comprising bio pharmaceuticals, is expected to grow at a rate of 30 per cent a year and reach US$100 billion by 2025.
Syngene to co-develop nutrition products for Herbalife
Business Standard-02/03/2017. It is Syngene's fifth dedicated facility and second for nutrition research, the lab is a testimony of its capabilities to deliver innovative solutions in wide industry segments.
Herbalife teams up with Syngene to develop, formulate nutrition products
The Hindu Businessline-02/03/2017. The new nutrition R&D facility will be housed within the Syngene campus, with around 10 Syngene scientists working on Herbalife formulations.
Clinical trials in India – Changing regulatory environment - by Dr. Chetan Tamhankar (Head -Clinical Development Services)
Pharmabiz-01/02/2017. The recent regulatory and policy changes announced by the government has once again made clinical trials in India lucrative for the global healthcare industry.
Syngene International Q3 net profit up 11.54% at Rs 74 cr
Outlook-24/01/2017. We made good progress on client service delivery across all of business verticals despite a fire incident damaging one of our research facilities, effective implementation of our business continuity plan..
Syngene International: Discover the chemistry
The Hindu Businessline-30/10/2016. From a pure play research services company, catering to the research needs of innovative pharma companies, Syngene is now repositioning itself as a fully integrated contract research and manufacturing company.
Syngene posts 55% rise in net profit
Live Mint-20/10/2016. Profit rose to Rs75 crore in the second quarter, from Rs48 crore a year earlier. Revenue rose 22% increase to Rs.319 crore from Rs.262 crore...
Syngene International acquires Strand Life Sciences’s assets.
Live Mint-22/09/2016. Syngene is constantly looking for new opportunities to expand its service offerings and plans to expand into areas such as NGS, translational R&D, predictive toxicology and pre-emptive target validation services, all of which require strong bioinformatics capabilities...
Syngene International Commissions Dedicated R&D Center for Amgen.
Financial Times-06/09/2016. The state-of-the-art dedicated center will be staffed by a team of more than 100 highly qualified Syngene scientists, working in close association with Amgen researchers around the world on the discovery and development of innovative medicines...